Bispecific antibody cevostamab shows 40% response rate in phase 1 multiple myeloma trial

A phase‑1 clinical trial of the investigational bispecific antibody cevostamab reported that more than 40 % of patients with relapsed or refractory multiple myeloma experienced a reduction in tumor burden. The study enrolled individuals who had previously undergone several lines of therapy, indicating that the drug may offer benefit even after standard treatments have failed.

Among the participants, the median duration of response was 11.2 months before disease progression was observed. This time frame suggests that cevostamab can sustain disease control for a substantial period in a heavily pre‑treated population, a key consideration for a condition that often progresses rapidly despite existing therapies.

The findings support continued clinical development of cevostamab, with further studies planned to confirm its efficacy and safety profile in larger, more diverse patient cohorts. If subsequent trials corroborate these early results, the antibody could become a new therapeutic option for patients with limited treatment choices.